Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies DOI Open Access
Kevin G. Shim, Rafaël Fonseca

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3288 - 3288

Published: Sept. 27, 2024

Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial real-world data, these demonstrated high rates of deep response, some are now approved second-line treatment relapsed MM. The sustained responses capable inducing will require sophisticated response monitoring to provide meaningful information patient care. Obtaining measurable residual disease (MRD) negativity has been validated as an independent positive prognostic marker progression-free survival (PFS) overall (OS) in newly diagnosed refractory patients with myeloma. Assessment MRD was performed all the trials FDA-approved TRT. Here, we summarize pertinent data assessment following TRT MM a rationale structured framework conducting testing post

Language: Английский

Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory’s experience: Unsatisfactory assay reproducibility DOI
Ian Cheong, Christopher Liang, Vipin Bhayana

et al.

Clinical Biochemistry, Journal Year: 2025, Volume and Issue: 138, P. 110941 - 110941

Published: May 8, 2025

Language: Английский

Citations

0
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse DOI
Lulu Kong, Kailin Xu, Wei Chen

et al.

Best Practice & Research Clinical Haematology, Journal Year: 2025, Volume and Issue: unknown, P. 101632 - 101632

Published: May 1, 2025

Language: Английский

Citations

0
CAR-T Therapy in Multiple Myeloma: Looking Beyond DOI Creative Commons
Gianluca Maiorana,

Giusy Antolino,

Giacinto La Verde

et al.

Hemato, Journal Year: 2024, Volume and Issue: 5(2), P. 180 - 198

Published: May 31, 2024

Multiple Myeloma is a hematological neoplasm that, over the recent few years, has benefited from numerous therapeutic options. Among latter, CAR-T stands out as most and one of promising treatments currently available. Despite its introduction, multiple products have already been approved, research regarding cellular therapy rapidly increasing. We conducted comprehensive search review available literature, including published studies abstracts meetings (ASH, ASCO, ASTCT, IMS), therapy. describe discovery targets like B-Cell Maturation Antigen (BCMA) others, origin nature cells, introduction anti-BCMA CAR-Ts Idecabtagene-vicleucel Ciltacabtagene-autoleucel, which are only approved for MM. Additionally, we discuss non-BCMA-targeting their clinical implications. Given significant impact therapy, provide an overview limitations possible adverse implications, well related resistance mechanisms. Finally, current aimed at improving in MM, structural innovations new approaches, such earlier lines treatment maintenance

Language: Английский

Citations

1
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies DOI Open Access
Kevin G. Shim, Rafaël Fonseca

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3288 - 3288

Published: Sept. 27, 2024

Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial real-world data, these demonstrated high rates of deep response, some are now approved second-line treatment relapsed MM. The sustained responses capable inducing will require sophisticated response monitoring to provide meaningful information patient care. Obtaining measurable residual disease (MRD) negativity has been validated as an independent positive prognostic marker progression-free survival (PFS) overall (OS) in newly diagnosed refractory patients with myeloma. Assessment MRD was performed all the trials FDA-approved TRT. Here, we summarize pertinent data assessment following TRT MM a rationale structured framework conducting testing post

Language: Английский

Citations

1